Cambridge 12th June 2023: Babraham Research Campus Ltd (BRC), the organisation which oversees the development and day-to-day management of the Babraham Research Campus is delighted to welcome Charlie Foreman to the Board as non-executive director.
Charlie is currently a Senior Strategic Advisor at Cambridge University Health Partners (CUHP), developing the funding pillar of the Life Sciences Strategy. He is also a Senior Advisor at Lazard, the world’s largest independent investment bank, having first joined Lazard as a Managing Director in December 2009, responsible…
BioIVT, a leading provider of biospecimens and ADME-Tox research products and services for drug and diagnostic development, today announced that it will be showcasing its expanded ADME-Tox portfolio at the 16th European ISSX and DMDG Meeting, which will be held from June 11-14 at the University of Hertfordshire in the UK.
“We’re looking forward to meeting with our research colleagues at ISSX. This is the first major conference at which we’ll be presenting our new integrated service portfolio since XenoTech joined BioIVT. We’re excited to be able to demonstrate how our expanded offerings…
Experienced life sciences logistics company, Biocair, has partnered with TrakCel and integrated their systems with OCELLOS to improve customer service, automation and visibility in the cell and gene therapy supply chain.
OCELLOS by TrakCel is an integrated cell orchestration solution designed to manage and streamline the cell, gene and immunotherapy supply chain. The platform ensures tracking of both chain of identity and chain of custody, both vital parts of the patient journey, to support the scalability of cell and gene therapy development.
Biocair has been delivering excellence in…
Presenters will discuss the ICH M12 Drug Interaction Studies Guideline, and novel ADME models and methodologies
BioIVT, a leading provider of biospecimens and ADME-Tox research products and services for drug and diagnostic development, today announced that it will be hosting an Advanced In Vitro ADME Strategies Symposium at the Scandic CPH Strandpark Hotel in Copenhagen, Denmark on June 9.
Symposium presenters will provide insights into how the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) M12 Drug Interaction Studies Guideline,…
Across the city, leading science companies and innovation parks will open their doors to showcase the cluster’s contribution to STEM innovation in the UK and strengthen its diverse, equitable and inclusive community.
Life Sciences is one of the UK’s most successful sectors, worth over £94 billion to the UK economy in 2021, a 9% increase on the year before. Last week the Chancellor revealed a £650 million multi-faceted ‘Life Sci for Growth’ package to support economic growth and help deliver the Science and Technology framework through reforming regulation, boosting investment and driving up…
Key executive appointment provides extensive financial industry experience as the Company implements ambitious global growth strategy
Cambridge, UK, 06 June 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced that it has appointed Dr. Samantha Macro as Chief Financial Officer. Samantha joins CEO, Dr. Paul Brooks, on the executive team to guide all key commercial and strategic initiatives, drive revenue and shape CN Bio’s ongoing growth trajectory.
Samantha’s appointment becomes CN…
Nottingham-based Contract Research Organisation (CRO) Cellomatics Biosciences has announced the appointment of Professor David Lambert, FRCA and FFPMRCA as Chief Scientific Officer (CSO).
Based in Nottingham, Cellomatics is a specialist preclinical CRO with expertise in five main therapeutic areas: oncology, immuno-oncology, immunology, inflammation and respiratory. Founded in 2015, Cellomatics has since positioned itself as the CRO of choice for its growing global client base seeking expert support with the development of bespoke bioassays.
David will retain a part-time contract at the…
AMSBIO announce MatriMix – a groundbreaking 3D culture substrate. This pioneering hydrogel sets a new benchmark in the field, containing fully defined components, including medical grade collagens, laminin-511 E8 fragments, and hyaluronic acid. The high lot-to-lot consistency of MatriMix enables researchers to obtain highly reproducible results.
MatriMix overcomes the limitations of current 3D substrates, enabling cutting-edge applications such as organoid formation using adult patient-derived cells and iPSC culture. MatriMix also demonstrates exceptional performance in in vivo animal PDX…
Check out this month's People Pathways newsletter where you can read about:
✅ON Helix Student Bursary✅Upcoming Training ✅Charles River events✅SRG's Salary Survey✅Many more...
Read it here